Searched for
SUN PHARMA BOFA
Sun Pharma shares slip 3% after BofA downgrade on premium valuationsBank of America downgraded Sun Pharma stock to ‘underperform’ from ‘neutral’, citing risks to premium valuations and slower speciality exec...- Dr. Reddy’s shares fall 6%, Aurobindo Pharma 10% as Trump signals 25% tariffs on pharma importsDr. Reddy’s Laboratories fell 5.8% to Rs 1,128.90, while Zydus Lifesciences dropped 4.8%. Sun Pharma, India's largest drugmaker, declined b...
- Sun Pharma's steady Q3 earnings prompt target upgrades by brokerages. Should you buy?The stock was trading with minor gains at the opening time and hit the day's high of Rs 1,430.45 on the NSE, up 0.84% over the Wednesday cl...
- Hot Stocks: Brokerages view on Paytm, Sun Pharma, M&M Financial and KEC InternationalThere could be revenue and profitability implications in the medium to long term and that would be a key item to monitor.
- If US avoids recession, how far can Nifty go? BofA analysts predictGlobal brokerage firm BofA said it sees Nifty inching ending December 2023 at 20,500 as returns have mostly been positive at least three mo...
- Hot Stocks: Brokerage view on BPCL, Sun Pharma, Thermax, Shree Cement and Power GridTop brokerage firms have released their recommendations for various companies. BofA Securities maintained an underperform rating on BPCL an...
- Hot Stocks: Brokerage views on Sun Pharma, Phoenix Mills, Kotak Mahindra Bank & M&MThe stock will likely go through a period of time correction, BofA said. The global investment sees a lack of meaningful catalysts in the n...
- Hot Stocks: Brokerages on Bharat Forge and Sun Pharma; JPMorgan see 28% upside in PNBBofA Securities maintained its buy rating on Sun Pharma with a target of Rs 1,000. Flattish llumya trend and the company is waiting for Win...
- Hot Stocks: Global brokerages see 12-15% return in HUL, RIL and Sun PharmaCitigroup maintained its buy rating on Hindustan Unilever with a target price of Rs 3050. The company announced entry into Health and well-...
- Hot Stocks: Brokerage on Tech Mahindra, Sun Pharma, and NykaaMacquarie maintained an outperform rating on Tech Mahindra with a target price of Rs 1230. Another brokerage firm BofA maintained a buy cal...
- Hot Stocks: Brokerages on Sun Pharma, Poonawalla Fincorp and Greaves CottonBofA Securities maintained buy rating on Sun Pharma with a target price of Rs 1030. The stock closed at Rs 879 on 26 August. There is some ...
- 12 stocks that are BofA Securities' top buys from 7 sectors. Do you own them?While BofA remained overweight on select domestic cyclicals such as industrials, financials and automobile stocks, it has marginally trimme...
- Top five Nifty50 stocks to buy which can give up to 20% return in 1 yearThe Nifty50 index has rallied around 800 points from 7,927 to 8,728 level and is making higher lows in the last seven consecutive weeks.
- Sun Pharma stock slumps 7%, SPARC 6%Shares of Sun Pharma and SPARC took a beating in Monday’s trade, falling as much as 7%, after the US FDA issued a warning letter to former’...
- Sun Pharma gains 2% as Street cheers latest USFDA approval for generic drugBrokering houses remained positive on the stock, with CLSA and Bank of America-Meryll Lynch (BofA ML) maintaining buy ratings on the scrip.
- Sensex ends 182 points higher, Nifty50 above 7,850; DRL cracks 8%, Tata Motors surges 6%The domestic equity market traded with smart gains on Thursday bucking the muted trend seen in other Asian and European markets.
- Profit of Sensex firms likely to fall 3.7% in Q2: BofA-MLAccording to Bank of America Merill Lynch (BofA-ML), 12 out of the 30 Sensex companies are expected to show a contraction in profits.
- Sun Pharma ends 4% up after BofA-ML upgradeThe global investment bank raised the target price to Rs 1070 for Sun Pharma shares from Rs 960 earlier.
- Market gives a thumbs-up to Ranbaxy deal; Sun Pharma and Daiichi Sankyo gainShares of Sun Pharma surged 2.68 per cent or Rs 15.35 to close at Rs 587.25 as the all-share deal’s swap ratio is seen to favour investors ...
- Brokerage views: Tata Steel, Sun Pharma, JP AssociatesDealers are expecting trade to remain choppy ahead of IIP and inflation data. Here's what they recommend to counter that.
Load More
